Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Leukemia, Hairy Cell

ClinicalTrials.gov lists 237 trials for Leukemia, Hairy Cell or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 34.

MeSH D007943 Neoplasms Neoplasm C04 C15 C20 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 69 Phase 1/2 Phase 1/2 16 Phase 2 Phase 2 58 Phase 2/3 Phase 2/3 1 Phase 3 Phase 3 22 Not applicable Not applicable 32 Observational Observational 37 Expanded access Expanded access 1 Phase 1 Phase 1 69 Phase 1/2 Phase 1/2 16 Phase 2 Phase 2 58 Phase 2/3 Phase 2/3 1 Phase 3 Phase 3 22 Not applicable Not applicable 32 Observational Observational 37 Expanded access Expanded access 1

Trials per phase (log scale)

1 more section with rows

237 of the 237 trials are tagged with Leukemia, Hairy Cell itself; the rest are tagged with a narrower condition beneath it.

Get the Leukemia, Hairy Cell report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Leukemia, Hairy Cell trials start? (33)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Not applicable
  • Observational
  • Unknown

Top of scale: 18

1991: 1 trials (Observational 1) 1992: 1 trials (Phase 2 1) 1995: 1 trials (Phase 2 1) 1996: 2 trials (Phase 2 1, Phase 1 1) 1997: 11 trials (Not applicable 2, Phase 3 1, Phase 2 1, Phase 1/2 1, Phase 1 6) 1998: 13 trials (Not applicable 1, Phase 3 2, Phase 2 3, Phase 1 7) 1999: 14 trials (Not applicable 2, Phase 3 4, Phase 2 1, Phase 1 7) 2000: 10 trials (Observational 1, Not applicable 2, Phase 3 3, Phase 2 1, Phase 1/2 2, Phase 1 1) 2001: 5 trials (Phase 3 1, Phase 2 1, Phase 1/2 1, Phase 1 2) 2002: 8 trials (Not applicable 3, Phase 3 1, Phase 2 1, Phase 1 3) 2003: 11 trials (Observational 1, Not applicable 3, Phase 2 2, Phase 1/2 3, Phase 1 2) 2004: 12 trials (Observational 2, Not applicable 3, Phase 2/3 1, Phase 2 4, Phase 1/2 1, Phase 1 1) 2005: 9 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2 5, Phase 1 1) 2006: 12 trials (Observational 3, Not applicable 2, Phase 3 2, Phase 2 5) 2007: 14 trials (Observational 3, Not applicable 1, Phase 3 1, Phase 2 3, Phase 1 6) 2008: 18 trials (Observational 7, Not applicable 1, Phase 3 3, Phase 2 3, Phase 1 4) 2009: 13 trials (Unknown 1, Observational 4, Not applicable 1, Phase 3 1, Phase 2 2, Phase 1/2 1, Phase 1 3) 2010: 13 trials (Observational 4, Not applicable 4, Phase 2 4, Phase 1 1) 2011: 5 trials (Not applicable 2, Phase 2 1, Phase 1/2 1, Phase 1 1) 2012: 9 trials (Observational 2, Not applicable 1, Phase 2 3, Phase 1 3) 2013: 8 trials (Phase 3 1, Phase 2 3, Phase 1/2 1, Phase 1 3) 2014: 8 trials (Phase 2 2, Phase 1 6) 2015: 3 trials (Not applicable 1, Phase 1/2 1, Phase 1 1) 2016: 2 trials (Phase 1/2 1, Phase 1 1) 2017: 1 trials (Phase 1/2 1) 2018: 1 trials (Phase 2 1) 2019: 2 trials (Observational 1, Phase 1 1) 2020: 6 trials (Phase 3 1, Phase 2 2, Phase 1 3) 2021: 4 trials (Observational 2, Phase 2 1, Phase 1 1) 2022: 6 trials (Observational 1, Phase 2 3, Phase 1 2) 2024: 6 trials (Observational 3, Phase 2 2, Phase 1 1) 2025: 1 trials (Not applicable 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 4
2025 1
2024 6
2022 6
2021 4
2020 6
2019 2
2018 1
2017 1
2016 2

Showing 10 of 33 earlier years.

Start your 14-day trial Email me all 33 earlier years as a PDF

No forecast is made for this condition: it averages 3.2 trial starts a year over the five years to September, under the 5 a year the method needs.

Prediction, not a registry value: median of 36 months from start to primary completion across 9 trials still running at the 2026-10-09 snapshot; registered median of 40 months across 179 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Leukemia, Hairy Cell trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 69
Phase 1/2 16
Phase 2 58
Phase 2/3 1
Phase 3 22
Not applicable 32
Observational 37
Expanded access 1
Unknown 1

How many Leukemia, Hairy Cell trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 2
Recruiting 14
Enrolling by invitation 1
Active, not recruiting 13
Completed 141

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Leukemia, Hairy Cell trials? (2)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 34
European Organisation for Research and Treatment of Cancer - EORTC 5

Which drugs are being tested for Leukemia, Hairy Cell? (3)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
RITUXIMAB 18
Cytoxan 18
Busulfan 8

Interventions as named in the registry (12)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Peripheral blood stem cell transplantation 26
SQ Fludarabine 19
Allogeneic (Allo) hematopoietic stem cell transplantation 16
Mofetil Mycophenolate 16
Cyclosporine 0.05% 15

Showing 5 of 12 interventions.

Start your 14-day trial Email me all 12 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Leukemia, Hairy Cell trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Death 157 2
Pneumonia 35 10
Graft versus host disease (GVHD) 34 1
Febrile neutropenia 33 13
Pyrexia 33 5

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Leukemia, Hairy Cell? (48)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Non-V600E BRAF mutations and treatment for hairy cell leukemia. Blood 2025 Yes
COVID-19 in patients with classic and variant hairy cell leukemia. Blood advances 2023 Yes
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia. Blood 2023 Yes
Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia. NEJM evidence 2023 Yes
Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy. Blood 2022 Yes

Showing 5 of 48 publications.

Start your 14-day trial Email me all 48 publications as a PDF

Prevalence (27)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Classic hairy cell leukemia Annual incidence 1-9 / 1 000 000 United Kingdom GB Unspecified
Classic hairy cell leukemia Annual incidence 1-9 / 1 000 000 United Kingdom GB Exact
Classic hairy cell leukemia Annual incidence 1-9 / 1 000 000 United Kingdom GB Exact
Classic hairy cell leukemia Annual incidence 1-9 / 1 000 000 United States US Exact
Classic hairy cell leukemia Annual incidence 1-9 / 1 000 000 United States US Exact

Showing 5 of 27 prevalence observations.

Start your 14-day trial Email me all 27 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Classic hairy cell leukemia 58017 Exact Orphadata Science knowledge files, Product 1
Classic hairy cell leukemia 58017 Exact Orphanet Rare Disease Ontology (ORDO)

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages